Riding high with GW Pharma

摘要

GW Pharmaceuticals seems poised to become the first drug producer to gain approval for a true cannabis-based drug for the treatment of epilepsy. The company unveiled positive data in March and is meeting with regulators later this quarter to expedite approval for its Epidolex, a drug derived from cannabis oil, for the treatment of epilepsy-induced seizures. Headquartered in the UK, GW Pharmaceuticals raised US$252m in an overnight equity offering last Tuesday that will fully fund the potential commercial launch of Epidolex.